|
GSK PLC on Thursday announced a vast decline in severe respiratory syncytial virus, or RSV, disease among people aged 60 years and older who were vaccinated with its RSV vaccine candidate.
GSK is a Brentford, London-based biopharmaceutical firm.
RSV is a common contagious virus affecting the lungs and breathing passages, with no vaccines currently available for treatment. GSK in June said it is close to developing the world's first RSV vaccine.
In a phase 3 trial, the vaccine candidate showed a 94% reduction in the severe RSV-lower respiratory tract disease, LRTD, when compared to a group who received a placebo. Overall, it demonstrated a 83% efficacy against the disease, which was high and consistent among RSV A and B strains.
Chief Scientific Officer Tony Wood said: ‘We believe that with the high vaccine efficacy demonstrated in this pivotal trial, our vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities.’
On Wednesday, GSK had said it will report a plethora of new data at the Infectious Disease Society of America's IDWeek 2022 annual meeting in Washington, DC between October 19 and 23. It will release 10-year efficacy and safety data on its shingles vaccine Shingrix, as well as results of its long-acting HIV treatment Vocabria/Rekambys in a clinical setting.
‘Submissions also include presentations from ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc and Shionogi & Co Ltd as shareholders, which will consist of abstracts from the companys diverse portfolio of innovative licensed treatment and prevention options,’ GSK said Wednesday.
GSK shares were down 0.8% to 1,348.00 pence each in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
